Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05472493
PHASE2

Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism

Sponsor: University of Calgary

View on ClinicalTrials.gov

Summary

This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18F\]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-01-01

Completion Date

2026-06-30

Last Updated

2024-07-24

Healthy Volunteers

No

Interventions

BIOLOGICAL

[18-F]CETO

PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.

Locations (1)

University of Calgary

Calgary, Alberta, Canada